Sign Out
APO-ERLOTINIB should be prescribed and managed only by a doctor who is experienced with anticancer drugs.
Patient must have a confirmed activating mutation of the EGFR-TK prior to starting of first-line APO-ERLOTINIB monotherapy.
Erlotinib has not been studied in patients with severely reduced liver function.
Erlotinib has not been studied in patients with severely reduced kidney function.
Serious side effects that have been reported with erlotinib include: liver failure, including fatal cases; gastrointestinal perforation (a hole through the wall of the stomach, small intestine, or large bowel) including fatal cases.
